Exploring omics signature in the cardiovascular response to semaglutide: Mechanistic insights and clinical implications
Rui Vitorino•October 14, 2024•3 citations
Chat with this paper
Extract insights, manage references, and accelerate your research
Continue your research
– It's free
Abstract
Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is a widely used drug for the treatment of type 2 diabetes that offers significant cardiovascular benefits.